An update is available for this article. Background: The prevalence of osteoporosis is
increasing in the United States. Purpose: To evaluate low bone mass and osteoporosis …

BACKGROUND: In 2007, the Agency for Healthcare Research and Quality (AHRQ)
published a systematic review on the comparative effectiveness of treatments for …

Background: Although several agents are available to treat osteoporosis, the relative
efficacy and toxicity of these agents when used to prevent fractures has not been well …

Antiresorptive drugs, such as the bisphosphonates and the RANKL inhibitor denosumab,
are currently the most widely used osteoporosis medications. These drugs increase bone …

An update is available for this article. Description: This guideline updates the 2017 American
College of Physicians (ACP) recommendations on pharmacologic treatment of primary …

Objective To review the comparative effectiveness of osteoporosis treatments, including the
bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in …

Background: Osteoporosis is a major contributor to the propensity to fracture among older
adults, and various pharmaceuticals are available to treat it. Purpose: To update a review …

Background: Optimal long-term osteoporosis drug treatment (ODT) is uncertain. Purpose: To
summarize the effects of long-term ODT and ODT discontinuation and holidays. Data …

Importance The clinical decision to initiate bisphosphonate therapy for the treatment of
osteoporosis requires balancing shorter-term harms and burdens (eg, gastroesophageal …

Studies examining real-world effectiveness of osteoporosis therapies are beset by
limitations due to confounding by indication. By evaluating longitudinal changes in fracture …